GoodRx (NASDAQ:GDRX) Price Target Raised to $5.00

GoodRx (NASDAQ:GDRX) had its price target boosted by Citigroup from $4.00 to $5.00 in a research note released on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the stock.

A number of other brokerages have also weighed in on GDRX. Leerink Partners set a $5.00 price objective on shares of GoodRx in a report on Thursday, August 6th. Weiss Ratings upgraded shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. TD Cowen boosted their target price on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday. Wells Fargo & Company increased their target price on GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $4.00 price target on shares of GoodRx in a research note on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $4.14.

GoodRx Stock Performance

Shares of GoodRx stock opened at $3.72 on Tuesday. GoodRx has a one year low of $1.77 and a one year high of $5.81. The company has a market cap of $1.27 billion, a PE ratio of 93.02, a P/E/G ratio of 1.70 and a beta of 1.60. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38. The business has a 50-day simple moving average of $3.01 and a 200-day simple moving average of $2.58.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The firm had revenue of $200.41 million for the quarter, compared to analysts’ expectations of $193.23 million. During the same quarter last year, the company earned $0.09 earnings per share. The firm’s revenue was down 1.3% compared to the same quarter last year. On average, equities research analysts forecast that GoodRx will post 0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Lazard Asset Management LLC grew its position in shares of GoodRx by 43.6% in the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock valued at $85,000 after buying an additional 5,201 shares during the last quarter. Brevan Howard Capital Management LP lifted its position in GoodRx by 7.7% in the third quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock valued at $404,000 after acquiring an additional 6,842 shares during the last quarter. Hirtle Callaghan & Co LLC boosted its stake in GoodRx by 60.3% in the fourth quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after acquiring an additional 6,869 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in GoodRx by 202.3% in the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after acquiring an additional 7,580 shares in the last quarter. Finally, Quarry LP acquired a new position in GoodRx in the third quarter valued at $33,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.